WDNA
WisdomTree BioRevolution ETF
NAV as of
4 Week: 15.23 - 16.79
52 Week: 15.23 - 18.81
Latest Closing Price
15.23
Premium / Discount
0.13
Expense Ratio
0.45%
Investment Objective
The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (“index”). The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.
Main Fund Characteristics
Performance
Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
---|---|---|---|
YTD | -12.26 | 1.19 | -10.33 |
1 Day | -0.45 | 0.00 | 0.00 |
1 Week | -4.99 | 1.42 | -3.52 |
1 Month | -6.80 | 4.58 | -1.49 |
3 Months | -12.78 | 8.62 | -1.48 |
6 Months | -7.75 | 13.04 | -0.59 |
1 Year | -11.01 | 21.96 | -0.50 |
2 Years | -42.93 | 35.47 | -1.21 |
3 Years | 0.00 | 0.00 | 0.00 |
5 Years | 0.00 | 0.00 | 0.00 |
10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | -26.0556 |
Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 80.0000 |
Dividend Frequency
Lastest Dividend
Ex Date | Payment Date | Dividend Payout per unit |
---|---|---|
22/12/2022 | 28/12/2022 | 0.0653 |
26/12/2021 | 29/12/2021 | 0.0246 |
Portfolio Data
Total Number of Holdings: 96
Number of Bond Holdings: 0
Number of Equity Holdings: 96
Total Market Value: 2,441,500
Portfolio Composition
Top 10 Holdings
% Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
---|---|---|---|---|---|
1 | BridgeBio Pharma Inc | 2.2774 | 2,040 | 0 | 56,569 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
Size | % of portfolio |
---|---|
Giant | 7.89 |
Large | 13.63 |
Medium | 33.56 |
Small | 17.66 |
Micro | 26.57 |
Equity Style Box Breakdown
0 | 0 | 0 | Large |
0 | 0 | 0 | Mid |
0 | 0 | 0 | Small |
Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
20.1793
Price/Book*
2.3144
Price/Sales*
2.2858
Price/Cash Flow*
13.3446
Dividend Yield*
0.8671
Growth Measures
Long-Term Earnings
11.7188
Historical Earnings
28.4356
Sales Growth
9.5236
Cash-Flow Growth
10.7423
Book-Value Growth
-3.3799
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
Detail | Value |
---|---|
Average Effective Duration | 0 |
Average Effective Maturity (Years)* | 0 |
Average Credit Quality | 0 |
Average Weighted Coupon* | 0 |
Average Weighted Price* | 0 |
Bond Style Box Breakdown
0 | 0 | 0 | High | Quality |
0 | 0 | 0 | Med | |
0 | 0 | 0 | Low | |
Ltd | Mod | Ext | ||
Interest-Rate Sensitivity |
Credit Quality
Type | % Bonds |
---|---|
N.A |
Bond Sector
Bond Maturity
% Bonds | |
---|---|
N.A |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.